Robert Nichols

A lifelong Chicago Cubs fan, Bob was raised with a sense of optimism and commitment that he’d later realize is perfectly matched to the pursuit of scientific discovery and innovation. After over a decade in basic science, Bob found drug discovery, and his beloved Cubs finally found their World Series trophy.

Bob has almost ten years of industry experience and is an original member of the RevMed team. A systems biologist by training, he spent six years in R&D before transitioning to the science/business interface, supporting corporate development and partnering, investor relations, and financing activities.

Bob joined Revolution Medicines at the founding of the company and has made significant contributions to the company’s pipeline, particularly development of its unique RAS(ON) inhibitor portfolio. He served as project team lead for the RMC-4630, RMC-6291 and RMC-8839 project teams, guiding all three through development candidate nominations and into preclinical development. On the corporate side, Bob has been an integral part of all aspects of partnering including scientific presentation, diligence, commercial assessment, modeling, and negotiations.

Bob received his Ph.D. in systems biology from the University of California at San Francisco, completed an EMBO training fellowship at the Centre for Genomic Regulation in Barcelona, and a postdoctoral training fellowship at Stanford University.